PhaseBio Pharmaceuticals is a biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The Company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance.